Novavax Hasn’t Delivered A Vaccine Yet, But The Stock May Be Worth A Look

Novavax Hasn’t Delivered A Vaccine Yet, But The Stock May Be Worth A Look

When the race to develop a Covid-19 vaccine began in early 2020, Novavax stock (NASDAQ: NVAX) was viewed as one of the front runners, with the company securing the largest funding from the U.S. government (about $1.6 billion). However, over a year and a half later, Novavax has yet to commercially..